Ascentage Pharma Group International ADR | Mid-cap | Healthcare
$40.08
2.06%
| Ascentage Pharma Stock Comparison:
Ascentage Pharma vs VertexAscentage Pharma vs RegeneronAscentage Pharma vs BridgeBio PharmaAscentage Pharma vs Blueprint MedicinesAscentage Pharma vs Legend BiotechAscentage Pharma vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 2.6B
Total Liabilities 2.3B
Shareholders Equity 274.2M
Debt to Equity 8.55

Cash Flow Metrics

Revenue & Profitability Trend

Ascentage Pharma Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i980.6M222.0M209.7M27.9M12.4M
Cost of Goods Sold i29.1M30.5M22.0M3.3M2.0M
Gross Profit i951.6M191.4M187.7M24.6M10.5M
Gross Margin % i97.0%86.2%89.5%88.1%84.2%
Operating Expenses
Research & Development i947.2M707.0M743.1M766.5M564.6M
Selling, General & Administrative i383.1M376.5M328.0M191.3M64.1M
Other Operating Expenses i-9.1M-19.4M-33.6M--
Total Operating Expenses i1.3B1.1B1.0B957.8M628.6M
Operating Income i-369.7M-872.6M-849.8M-869.8M-663.9M
Operating Margin % i-37.7%-393.1%-405.2%-3,116.6%-5,332.9%
Non-Operating Items
Interest Income i37.8M32.4M9.7M7.1M5.2M
Interest Expense i64.5M96.1M52.8M16.7M6.3M
Other Non-Operating Income1.1M3.4M5.7M--
Pre-tax Income i-395.3M-932.9M-887.2M-832.2M-675.4M
Income Tax i10.4M-7.2M-4.2M-49.8M2.2M
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-405.7M-925.7M-882.9M-782.4M-677.6M
Net Margin % i-41.4%-417.0%-421.0%-2,803.4%-5,442.6%
Key Metrics
EBITDA i-243.4M-747.4M-780.5M-847.9M-638.0M
EPS (Basic) i-$-13.12$-13.40$-3.07$-3.14
EPS (Diluted) i-$-13.12$-13.40$-3.07$-3.14
Basic Shares Outstanding i-705748176592220718554836971573610657
Diluted Shares Outstanding i-705748176592220718554836971573610657

Income Statement Trend

Ascentage Pharma Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i1.2B1.1B1.5B1.7B1.0B
Short-term Investments i-----
Accounts Receivable i83.1M145.9M54.4M54.0M0
Inventory i6.6M16.2M9.4M3.9M0
Other Current Assets-----
Total Current Assets i1.5B1.3B1.6B1.9B1.1B
Non-Current Assets
Property, Plant & Equipment i00648.7M9.9M1.9M
Goodwill i125.4M134.8M133.7M109.8M146.8M
Intangible Assets i76.0M85.4M84.3M60.4M97.4M
Long-term Investments-----
Other Non-Current Assets100.8M66.9M62.1M45.8M52.1M
Total Non-Current Assets i1.1B1.2B1.2B1.1B652.0M
Total Assets i2.6B2.5B2.8B2.9B1.7B
Liabilities
Current Liabilities
Accounts Payable i92.0M72.4M95.6M70.9M23.4M
Short-term Debt i779.1M616.4M518.4M49.5M50.6M
Current Portion of Long-term Debt-----
Other Current Liabilities--2.8M-10.1M
Total Current Liabilities i1.2B934.2M881.2M361.1M276.1M
Non-Current Liabilities
Long-term Debt i889.4M1.2B1.3B1.0B479.1M
Deferred Tax Liabilities i5.4M10.5M12.2M13.8M15.4M
Other Non-Current Liabilities6.3M----
Total Non-Current Liabilities i1.2B1.5B1.5B1.3B608.3M
Total Liabilities i2.3B2.4B2.4B1.7B884.4M
Equity
Common Stock i214.0K197.0K180.0K178.0K154.0K
Retained Earnings i-5.8B-5.4B-4.4B-3.6B-2.8B
Treasury Stock i8.0K21.4M26.6M3.0K4.0K
Other Equity-----
Total Shareholders Equity i274.2M70.6M408.7M1.2B846.6M
Key Metrics
Total Debt i1.7B1.8B1.8B1.1B529.7M
Working Capital i307.6M410.0M755.3M1.5B802.9M

Balance Sheet Composition

Ascentage Pharma Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-395.3M-932.9M-887.2M-832.2M-675.4M
Depreciation & Amortization i93.2M93.2M62.9M--
Stock-Based Compensation i20.9M31.5M22.1M47.0M74.0M
Working Capital Changes i46.9M-49.9M43.8M142.0M-1.8M
Operating Cash Flow i-169.9M-762.0M-705.7M-608.7M-575.1M
Investing Activities
Capital Expenditures i-24.3M-46.1M-200.9M-435.1M-249.9M
Acquisitions i-25.5M-20.0M-20.0M-36.2M0
Investment Purchases i---130.0M-1.8B-2.2B
Investment Sales i--01.8B2.3B
Investing Cash Flow i-49.8M-66.1M-350.9M-465.3M33.7M
Financing Activities
Share Repurchases i0-5.9M-26.8M-25.9M0
Dividends Paid i000--
Debt Issuance i535.9M953.5M763.6M599.7M527.8M
Debt Repayment i-681.3M-966.9M-67.7M-51.2M-95.0M
Financing Cash Flow i375.3M461.1M669.1M1.8B1.1B
Free Cash Flow i-135.6M-782.9M-890.9M-1.0B-861.4M
Net Change in Cash i155.6M-367.0M-387.6M749.4M523.5M

Cash Flow Trend

Ascentage Pharma Key Financial Ratios

Valuation Ratios

Forward P/E 41.75
Price to Book 47.22
Price to Sales 3.81

Profitability Ratios

Profit Margin -41.34%
Operating Margin -361.23%
Return on Equity -235.32%
Return on Assets -9.25%

Financial Health

Current Ratio 1.26
Debt to Equity 608.58
Beta 0.83

Per Share Data

EPS (TTM) $-0.75
Book Value per Share $0.85
Revenue per Share $12.99

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
aapg3.7B-47.22-235.32%-41.34%608.58
Vertex 120.6B32.827.32-5.64%-8.91%10.00
Regeneron 60.8B14.312.0315.96%31.94%9.20
BridgeBio Pharma 8.8B-16.08-36.76%98.25%-1.13
Blueprint Medicines 8.4B-120.9924.43-47.71%-27.70%208.50
Legend Biotech 8.0B-45.177.84-20.00%-29.95%35.65

Financial data is updated regularly. All figures are in the company's reporting currency.